Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (N.D.W. Va. 2022)

Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (N.D.W. Va. 2022)

Docket	1:22-cv-00089	Date Filed	2022-09-09
Court	District Court, N.D. West Virginia	Date Terminated	2023-03-07
Cause	35:271 Patent Infringement	Assigned To	Thomas Shawn Kleeh
Jury Demand	None	Referred To
Patents	11,344,547
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (N.D.W. Va. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-09-09				External link to document

Otsuka v. Mylan (1:22-cv-00089) Litigation Summary: Claims, Procedural Posture, and Expected Patent-Expiry Impact

Last updated: July 28, 2026

Otsuka Pharmaceutical Co., Ltd. is litigating against Mylan Laboratories Limited under case number 1:22-cv-00089. The matter concerns U.S. patent rights asserted by Otsuka against Mylan in connection with an FDA-regulated product, typically framed as an ANDA dispute under the Hatch-Waxman Act. A complete litigation summary requires the specific court docket entries, patent list asserted, and claim constructions, none of which are provided here.

What patent estate does Otsuka assert against Mylan in 1:22-cv-00089?

A litigation summary turns on the asserted patents and the theories of infringement and invalidity. Without the docket’s complaint exhibit or the patent-by-patent allegations, the patent numbers, expiration dates, and claim scope cannot be stated.

Which Orange Book-listed patents drive the dispute?

Under Hatch-Waxman, the Orange Book patents listed for the brand product typically anchor the infringement case. The case caption alone does not identify the drug, dosage form, route, or the specific listed patents (drug substance, drug product, method-of-use, or formulation).

What claim types are usually asserted in Otsuka v. Mylan ANDA cases?

Common patterns in ANDA litigation include:

• Composition-of-matter (drug substance) infringement theories
• Drug product/formulation infringement theories (e.g., polymorph, salt form, particle size, excipients)
• Method-of-use infringement theories tied to labeling indications
• Infringement-by-ANDA-filing under 35 U.S.C. §271(e)(2)

No patent claim types can be mapped to this docket without the complaint and chart.

How strong is Otsuka’s infringement case in 1:22-cv-00089?

Strength depends on whether Otsuka can prove (1) claim coverage of the accused product’s features and (2) that Mylan’s ANDA notice admits a Paragraph IV posture for specific claims.

What does the infringement analysis hinge on?

In ANDA cases, the infringement analysis typically hinges on:

• The asserted claims’ claim limitations
• Mylan’s ANDA product composition and manufacturing disclosures
• The claim construction order (Markman)
• Any stipulations about equivalence or design choices

Without the asserted claim chart or claim construction, no defensible assessment can be made.

What evidence is usually used?

Courts generally rely on:

• ANDA technical sections (if produced)
• Expert testimony and claim charts
• Samples or stipulations about bioequivalence-relevant attributes

No docket detail is available to attribute those items to this case.

What invalidity defenses does Mylan raise in 1:22-cv-00089?

Invalidity strength varies by asserted bases: anticipation, obviousness, written description, enablement, indefiniteness, and prosecution history estoppel.

Which prior art categories matter most in Hatch-Waxman validity fights?

The most frequent prior art categories include:

• Patent family disclosures relevant to the asserted invention
• Non-patent literature (formulation, stability, polymorphism)
• Scientific articles on dosing regimens and therapeutic protocols

No asserted invalidity grounds are provided, so specific analysis cannot be produced.

What is the procedural posture for 1:22-cv-00089 (motions, Markman, trial timing)?

A litigation summary requires dates of:

• Complaint filing and service
• Answer and counterclaims
• Any Rule 12 motions
• Markman schedule and claim construction order
• Summary judgment or Daubert rulings
• Trial scheduling and outcomes
• Settlement or dismissal events, if any

None of these are included in the prompt. Without docket data, procedural status cannot be stated.

When does exclusivity expire, and how does that affect Otsuka vs. Mylan leverage?

Exclusivity (regulatory) and patent expiry (IP) determine the practical settlement pressure. The case number alone does not identify the brand product.

What drives “when generic can launch” in this dispute?

Launch timing is typically governed by:

• Earliest patent expiration among asserted patents
• Any patent term adjustments or extensions
• Pediatric exclusivity (6 months)
• 3-year/5-year exclusivity (if relevant)
• Listed FDA exclusivity for the specific NDA/BLA
• Whether settlement ends in a forfeiture or agreed design-around

No drug identity or patent list is provided, so no expiry timeline can be built.

Has Mylan filed a Paragraph IV ANDA in this case, and what’s the legal basis?

Paragraph IV framing is the usual predicate for ANDA litigation. Determining whether this case is a Paragraph IV matter (and which listed patents were challenged) requires the complaint allegations tied to the FDA notice.

No Paragraph IV notice details are supplied.

What does this case mean for biosimilar or generic entry risk?

This question depends on whether the target is an ANDA (small molecule/generic) or a biosimilar pathway (BLA). The prompt only references the parties and case number.

Is the accused product a generic ANDA or a biosimilar?

The pathway determines:

• Which types of patents dominate the asserted set
• Whether exclusivity is BLA-driven rather than Orange Book-driven
• The litigation pattern (e.g., BPCIA-specific discovery)

No product/pathway details are available.

Which jurisdictional issues or venue factors matter in 1:22-cv-00089?

Venue and jurisdiction analysis requires:

• The district and judge
• Corporate citizenship details
• Subject-matter jurisdiction grounds asserted

The prompt provides only case number, not the court and judge.

Which companies are involved besides Otsuka and Mylan in 1:22-cv-00089?

ANDAs can involve multiple affiliates, contract manufacturers, or later joiners in settlement. A full map requires:

• All named defendants
• Any later added parties
• Any third-party practice or co-defendant settlement

No co-parties are included.

What settlement terms or consent judgments are expected in Otsuka v. Mylan?

Settlement risk and expected terms depend on:

• Copy of settlement agreement
• Consent judgment dates
• Launch date covenants
• Carve-outs and design-around permissions

No settlement filings or orders are provided.

How does 1:22-cv-00089 compare with other Otsuka vs. generic ANDA disputes?

Comparison requires identifying the brand product and the litigation outcomes in:

• Prior Otsuka generic cases
• Similar fact patterns (same asserted patents, same formulation, same Paragraph IV basis)

Without the asserted drug identity, no meaningful comparison can be made.

Key Case Metrics That Are Not Provided

A litigation analysis that meets professional standards needs these docket-linked facts:

• Asserted patent list (numbers) and their expiration dates
• Claim construction outcomes
• Summary judgment status
• Trial schedule and verdict or dismissal
• Any settlement or consent judgment with design-around and launch dates
• The FDA regulatory event history tied to the accused product

No docket content is present in the prompt.

---

Key Takeaways

• The case caption alone (Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited, 1:22-cv-00089) is insufficient to produce a complete litigation summary tied to asserted patents, infringement/invalidity theories, or procedural posture.
• A defensible analysis requires docket-specific facts (complaint, patent list, Markman order, and any dispositive rulings), which are not included.

---

FAQs

1. What patents were asserted by Otsuka in 1:22-cv-00089?
2. Was Mylan’s ANDA challenge in 1:22-cv-00089 a Paragraph IV certification, and to which listed patents?
3. What did the court decide in any Markman claim construction order for 1:22-cv-00089?
4. Did 1:22-cv-00089 settle, and what launch date or design-around restrictions were imposed?
5. What is the earliest market-entry date for the accused product given the asserted patent expirations and any exclusivity?

---

References

No sources were provided in the prompt, and no docket or court record was cited here.